Korsana Biosciences, Inc. (KRSA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jonathan Violin M.B.A., Ph.D.
|
President, CEO, Secretary & Director | -- | -- | 1975 |
|
Dr. Mark Joseph Vignola Ph.D.
|
Chief Financial Officer | -- | -- | 1978 |
|
Dr. Gan Wei Ph.D.
|
Chief Technical Officer | -- | -- | -- |
|
Dr. Matthew Leoni M.D.
|
Chief Medical Officer | -- | -- | -- |
|
Mr. Kyle Breidenstine CPA, M.B.A.
|
Senior Vice President of Finance & Treasurer | -- | -- | -- |
Korsana Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 19
Description
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
